Across TCGA pan-cancer cohorts, URAD Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated URAD data layer compared with 21 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher URAD Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated URAD expression acts as an unfavorable survival marker.

PRAD and SARC are the cancer types where URAD Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	OS	Median	All	0.174	0.883	<.001	12	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: URAD tumor-vs-normal RNA expression · all URAD data types